The Clyde Biosciences team are delighted to have been shortlisted for an award in February’s Scottish Life Sciences Awards.
One of three finalists in the Innovative Collaboration award, Clyde has been recognised for its contribution to a global initiative designed to improve the way drugs are assessed for cardiac safety.
The initiative, known as CiPA (Comprehensive in vitro Proarrhythmia Assay) is led by the US FDA with Clyde’s Chief Scientific Officer Professor Godfrey Smith providing scientific leadership over one of its core programmes.
CellOPTIQ, Clyde Biosciences’ unique assay system, performed extremely well in a large multinational study. The data from this study, when published later this year, will cement Clyde’s place in the global drug safety community.
In addition to the FDA this project has seen Clyde collaborating with Abbvie, Eisai, Merck, BMS, Genentech and Janssen.
This initiative has placed BioCity-based Clyde Biosciences at the heart of cardiac safety worldwide.